Mertiva AB

About Us

Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid assets and holdings in Protein Sciences Corporation and Mercodia AB. Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Quarterly Report I 09/10

Fri, Jan 29, 2010 08:44 CET

First quarter report for Diamyd Medical AB (publ), fiscal year 2009/2010 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)First quarter, September 1 – November 30, 2009 • The last patient was included in the European Phase III study of the Diamyd® diabetes vaccine. • The US Department of Veterans Affairs (VA) awarded a grant of USD 1.84 million to support the development of Diamyd’s Nerve Targeting Drug Delivery System (NTDDS) for Diabetic Neuropathic Pain. • An oversubscribed preferential rights issue brought in just over MSEK 219 before issue expenses to Diamyd. • Diamyd

Diamyd Technology Advances with US $ 1.84 Million Grant

Tue, Nov 10, 2009 08:28 CET

Diamyd Inc, Pittsburgh, PA, USA, a wholly-owned subsidiary of Diamyd Medical, Stockholm Sweden, announces today that the United States Department of Veterans Affairs (VA) has awarded a $1.84 million grant to support the development of Diamyd’s Nerve Targeting Drug Delivery System (NTDDS) for Diabetic Neuropathic Pain.The two-year grant largely funds the advancement of NTDDS with Glutamic Acid Decarboxylase (GAD) through preclinical efficacy, toxicology and biodistribution studies, manufacturing and filing of an Investigational New Drug (IND) application with the Food and Drug Administration

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Quarterly Report I 09/10

Diamyd Technology Advances with US $ 1.84 Million Grant

Media